Inventiva (IVA) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Inventiva is gearing up for its Combined General Meeting on December 11, 2024, where shareholders will vote on crucial resolutions, including a financing plan of up to 348 million euros and the appointment of new directors. The biopharmaceutical company, known for its work on MASH/NASH treatments, is advancing its clinical pipeline, with lanifibranor in a Phase 3 trial and plans for further development activities. This meeting marks a significant step for Inventiva as it navigates its strategic and financial future.
For further insights into IVA stock, check out TipRanks’ Stock Analysis page.
